ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases Press release My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S. February 06, 2020
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day Press release LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. January 29, 2019
ProQR Announces Financial Results for the Third Quarter of 2018 Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 07, 2018
ProQR Announces Financial Results for the Second Quarter of 2018 Press release LEIDEN, The Netherlands, Aug. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. August 08, 2018
ProQR to Host R&D Day in New York on January 29 Press release … (formerly named QR-110) for LCA10 and QR-421a for Usher syndrome and discussion of the next therapies to enter … January 03, 2019
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Press release Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome December 08, 2023
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board Press release Key Updates November 09, 2017
ProQR to Present at Three Scientific Conferences in April Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 22, 2019
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 Press release LEIDEN, The Netherlands and CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 15, 2019